Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in Systemic Lupus Erythematosus
NCT06857214Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emfizatamab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 8 more. Started Jun 2025; status: recruiting.
02
Drugs
emfizatamab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06857214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857214.